ライフサイエンスコーパス: PRP

1 PRP activity remained unchanged in the untreated MPTP he

2 PRP activity was also stable (P >/= 0.29) and correlated

3 PRP activity was elevated in the untreated MPTP hemisphe

4 PRP activity was measured prospectively in all animals a

5 PRP also inhibits primary and secondary sphere formation

6 PRP and PPP showed a similar protein profile and exerted

7 PRP compared with IVR as primary treatment for PDR is le

8 PRP expressed antibacterial properties, which may be att

9 PRP formulation was proven to inhibit in vitro angiogene

10 PRP impaired engrafting of pancreatic CSC's tumours in n

11 PRP increased cartilage surface cell density 1.5-fold (P

12 PRP interfered with P. gingivalis and A. actinomycetemco

13 PRP structures are dominated by four-sided right-handed

14 PRP was completely done for all eyes in group I after th

15 PRP- BMA presented higher numbers of PCNA-positive and B

16 From 2012 through 2019, 10 035 PRP or anti-VEGF treatments were administered to 3685 PD

17 ided into four groups: 1) C (control) and 2) PRP, defects were filled with blood clot or PRP, respect

18 ) of 22 IVB-treated eyes and in 1 (3%) of 32 PRP-treated eyes.

19 ession in the stele of hairy roots for all 4 PRP genes tested, with additional expression in the cort

20 od clot or PRP, respectively; 3) LLLT and 4) PRP/LLLT, defects received laser irradiation, were fille

21 lative probability of worsening PDR was 42% (PRP) versus 34% (ranibizumab; hazard ratio [HR], 1.33; 9

22 in many states) at 2 years compared with 82 PRP participants (87%, adjusted risk ratio = 1.1, 95% CI

23 rt failure with reduced ejection fraction, a PRP distinguished patients who derived substantial survi

24 Additionally, PRP coacervate doubled the rate of wound contraction com

25 with persistent PDR (pPDR) despite adequate PRP were prospectively followed on a monthly basis with

26 After PRP, both SS OCTA and FA demonstrated similar progressio

27 PRP and 1 week, 1 month, and 3 months after PRP confirmed that the precursor IRMA lesions were intra

28 Three months after PRP, FA demonstrated profuse leakage from 3 new NV lesio

29 on WF SS-OCTA images through 3 months after PRP.

30 was obtained at baseline and 3 months after PRP.

31 e and at 1 week, 1 month, and 3 months after PRP.

32 e and at 1 week, 1 month, and 3 months after PRP.

33 were obtained at baseline and 3 months after PRP.

34 ed to study gene expression regulation after PRP treatment and resulted in, (i) epithelial-mesenchyma

35 tified at baseline and imaged serially after PRP using WF SS-OCTA.

36 tified at baseline and imaged serially after PRP using wide-field SS OCTA.

37 n in PDR does not change significantly after PRP.

38 significant changes in RNP area 1 year after PRP.

39 of intravitreal injection of conbercept and PRP can significantly reduce the NV of PDR patients and

40 At 30 days, control and PRP-BMA groups presented similar amounts of NBA and ABT;

41 to treatment (days between PDR diagnosis and PRP) and medical comorbidities (coronary artery disease

42 Both IVB and PRP are effective treatment options for type 1 ROP with

43 ent for zone I ROP eyes treated with IVB and PRP were -3.7 D and -10.1 D, respectively, and for zone

44 Distinguishing the effects of PDR and PRP may guide the development of restorative vision ther

45 es were compared among patients with PDR and PRP, untreated patients with PDR, and controls.

46 We used washed platelets and PRP, standard laboratory HIT tests, and physicochemical

47 racterize and compare the effects of PPP and PRP on bone healing in vivo.

48 Assays on reconstituted PRP and PRP from fibrinogen-deficient patients revealed a fibrin

49 g DME, 80 and 87 were in the ranibizumab and PRP groups, respectively.

50 rofiles with hypoxia or oxidative stress and PRP-overexpressing plants have elevated levels of reacti

51 When choosing between anti-VEGF and PRP as first-line therapy for PDR, treatment decisions s

52 e absent from root epidermal cell walls, and PRP accumulation is highly localized within the walls of

53 PRPs, all of which cross-react with the anti-PRP antibodies.

54 The findings reveal that locally applied PRP enhanced the maturity of the healing tendon tissues

55 As datamining associates PRP expression profiles with hypoxia or oxidative stress

56 inical experiences were assessed by baseline PRP treatment status.

57 Swept-source OCTA performed before PRP and 1 week, 1 month, and 3 months after PRP confirme

58 rage lifetime, the cost differential between PRP and IVR increases, and IVR therapy may exceed the ty

59 ve patients with PDR that required bilateral PRP.

60 ar-dependent occlusion and lag time for both PRP and WB.

61 rols (1.80+/-0.14) also was observed in both PRP-treated patients (1.42+/-0.17; P < 0.0001) and untre

62 e same agent and 7.7% were treated with both PRP and anti-VEGF agents.

63 vitreal injection of aflibercept followed by PRP and early vitrectomy are effective and safe modaliti

64 three successive IVA injections followed by PRP and group IotaIota (17 eyes) for whom early vitrecto

65 Bacterial growth inhibition by PRP occurred in the first 24 hours after application in

66 Self-setting alginate hydrogel carrying PRP was tested on a femur defect model ex vivo.

67 the PRP by progressively syphoning clarified PRP away from the concentrated leukocyte flowstream.

68 d the other eye received conbercept combined PRP.

69 Consequently, PRP could have relevant oncological clinical application

70 Hospital admissions significantly delayed PRP delivery.

71 d platelets or immunoglobulin (Ig)G-depleted PRP.

72 IgG or monoclonal IgG1 added to IgG-depleted PRP increased the lag time in response to 5B9.

73 both enhance PRP photodegradation and divert PRP dissipation processes away from the production of 34

74 In eyes without DME, PRP use declined from 1017/1000 in 2012 to 707/1000 in 2

75 rrigation with such water would both enhance PRP photodegradation and divert PRP dissipation processe

76 At enrollment, PRP symptoms had persisted in 36 patients (72%) for an a

77 In the natural environment, we expect PRP photodegradation to be important only in the presenc

78 Filtrate PRP collected from an optimally-designed CIF device typi

79 all capillary layers in the macula following PRP, unrelated to macular edema or thickening, in line w

80 or the vascular density parameters following PRP, except for decreased density at the MCP at the late

81 f blood flow to the posterior pole following PRP, adding a new dimension to our understanding of the

82 s (D) and 22.4 months, respectively, and for PRP-treated eyes, these were -5.3 D and 37.1 months, res

83 although longer follow-up was available for PRP.

84 treatments broadens therapeutic options for PRP in proliferative diabetic retinopathy.

85 ncreased lag time and decreased RPA rate for PRP compared to WB (p < 0.01), the device with a shorter

86 Cost utility for PRP would be 85% lower than IVR in the facility setting

87 all other treatments, including that of free PRP proteins.

88 PRP were randomly assigned to 1 of 4 groups: PRP conventional pattern 30 ms, 100 ms, navigated patter

89 es with 2 years of follow-up, 43 (62.3%) had PRP, 16 (23.2%) were treated with injections alone, and

90 Of the 111 eligible eyes, 55 (49.5%) had PRP, 35 (31.6%) were managed with injections alone, and

91 nion exchange chromatography with a Hamilton PRP-X100 column as the stationary phase.

92 [95% CI, 0.04-0.51]; P=0.0075) but not high PRP score (n=937; hazard ratio, 0.84 [95% CI, 0.53-1.3];

93 Our mathematical model explained how PRP would increase macular blood flow.

94 However, PRP can damage the retina, resulting in peripheral visio

95 However, PRP samples had fewer blood vessels than did control sam

96 In PRP-treated eyes, retinal detachment developed in only 1

97 cipants (104 in aflibercept group and 106 in PRP group) within per protocol.

98 rticipants (112 in aflibercept group, 109 in PRP group) contributed to the modified intention-to-trea

99 ase report, a role of the IL-23-TH17-axis in PRP was identified, suggesting a shared pathogenic infla

100 ut learning, and odorant-elicited changes in PRP increase for rewarded and decrease for unrewarded od

101 In contrast, in PRP from patients with severe hemophilia, PN-1 neutraliz

102 In patients with diagnosed PDR, a delay in PRP treatment beyond 31 days was associated with worse v

103 of FDP mean deviation (MD) was exhibited in PRP-treated patients with PDR (MD +/- standard deviation

104 nt of collagen I was significantly higher in PRP-treated tendons than in control tendons (p=0.0079),

105 glycans content were significantly higher in PRP-treated tendons than in controls (p=0.01 and p<0.001

106 III to collagen I was significantly lower in PRP samples (p=0.007).

107 ified Bonar score was significantly lower in PRP samples, which indicates improved early tendon heali

108 s between the groups tested, TGA measured in PRP with CTI best differentiated between bleeders and no

109 rns specific for maturation were mimicked in PRP treated cartilage, with chondromodulin, collagen typ

110 tokine profile, targeted treatment option in PRP.

111 Contact phase activation by polyphosphate in PRP resulted in 75% cleavage of chem163S.

112 ignificantly improved thrombin production in PRP, underlining the regulatory role of PN-1 released fr

113 (*)OH and CO3(*-) would play a major role in PRP phototransformation.

114 okines IL-17A, IL-17F, and IL-22 was seen in PRP.

115 e number of sittings to complete the initial PRP.

116 investigating the effects of multispot laser PRP on retinal sensitivity demonstrates a high likelihoo

117 In lesional PRP skin samples from a single patient, upregulated expr

118 ced all-cause mortality in patients with low PRP score (n=251; hazard ratio, 0.19 [95% CI, 0.04-0.51]

119 In a porcine model, PRP coacervate significantly accelerated the healing res

120 of sham-treated patients underwent 1 or more PRP treatments through month 24, compared with 1.1% and

121 of sham-treated patients underwent 1 or more PRP treatments through month 24.

122 nogen A was determined at a ratio 1:6 (named PRP) using 24 human cancer cell lines.

123 ed proliferation of MSCs, and 2.5% to 10% of PRP gradually increased alkaline phosphatase (ALP) activ

124 Atomic force microscopy analysis of PRP and growth factor treated cartilage gave a 5-fold in

125 The application of PRP on periodontal surgical sites is advisable because o

126 thors evaluated the growth factor content of PRP and PPP using a proteome profiler array and enzyme-l

127 hemical (probably biological) degradation of PRP.

128 undred patients with a putative diagnosis of PRP and who elected to participate completed a comprehen

129 Patients with a diagnosis of PRP were solicited through patient support organization

130 criminate the odorants the dimensionality of PRP decreases.

131 ined osteogenic and mineralization effect of PRP and BMP2 on MSCs was studied.

132 The effect of PRP and PPP on HPLSC bone differentiation was analyzed b

133 The effect of PRP at day 15 on the closure of the embryonic mouse calv

134 The antiangiogenic effect of PRP was analysed by matrigel-based tube formation and by

135 To model the hemodynamic effect of PRP, we also present a mathematical model based on elect

136 no published study exists of the effects of PRP in human tissues in vivo.

137 rstanding of the complex biologic effects of PRP in PDR.

138 es demonstrated high anti-tumour efficacy of PRP against tumours induced by BxPC3 human pancreatic CS

139 Transgenic over-expression of PRP, the founding member, led to plants with enhanced re

140 ity (VA) 20/320 or better, and no history of PRP.

141 isual acuity 20/320 or better, no history of PRP.

142 Increase of PRP concentration promoted proliferation of MSCs, and 2.

143 rative diabetic retinopathy (PDR) in need of PRP were randomly assigned to 1 of 4 groups: PRP convent

144 ese results suggest that this preparation of PRP accelerates healing of cutaneous wounds only as a co

145 rentiation in vitro and sustained release of PRP alone on a fracture defect model ex vivo as well as

146 Sustained release of PRP along with BMP2-modified MSCs can significantly prom

147 Sustained release of PRP and BMP2 demonstrated significantly higher ALP and m

148 the combined effect of sustained release of PRP from alginate beads on BMP2-modified MSC osteogenic

149 ermine the longer term effects of the use of PRP in musculoskeletal diseases.

150 ivation, was quantified by flow cytometry on PRP.

151 nts (OR, 1.61; P = .038); and receiving only PRP compared to only IVIs (OR, 1.93; P = .031).

152 surement is especially important to optimize PRP for applications using short pulse duration.

153 lt patients with PDR who received IVI and/or PRP between January 1, 2014, and June 1, 2018, at the au

154 irradiation, were filled with blood clot or PRP, respectively, and then irradiated again.

155 PRP, defects were filled with blood clot or PRP, respectively; 3) LLLT and 4) PRP/LLLT, defects rece

156 data from infants treated with either IVB or PRP for type 1 ROP between 2008 and 2012 were recorded f

157 ibercept injections were given as needed) or PRP standard care (single spot or mutlispot laser at bas

158 ased on a structured retreatment protocol or PRP at baseline for PDR.

159 g either intravitreal anti-VEGF treatment or PRP with the next follow-up visit occurring more than 6

160 ng-related outcomes favored ranibizumab over PRP, no differences between treatment regimens for PDR w

161 ed a parkinsonism-related metabolic pattern (PRP) in nonhuman primate models of PD.

162 odorant rewarded?) can be decoded from peak PRP in animals proficient in odorant discrimination, but

163 ess visual field loss, continuing to perform PRP may be justified.

164 anaged by panretinal laser photocoagulation (PRP) for the past 40 years.

165 e the effect of panretinal photocoagulation (PRP) associated with intravitreal conbercept injections

166 Panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) may le

167 out preexistent panretinal photocoagulation (PRP) had a higher risk to undergo supplemental treatment

168 efore and after panretinal photocoagulation (PRP) in eyes with treatment-naive proliferative diabetic

169 efore and after panretinal photocoagulation (PRP) in treatment-naive eyes with proliferative diabetic

170 Panretinal photocoagulation (PRP) is the standard treatment for reducing severe visua

171 es treated with panretinal photocoagulation (PRP) or ranibizumab.

172 injection with panretinal photocoagulation (PRP) versus early vitrectomy for diabetic vitreous hemor

173 alternative to panretinal photocoagulation (PRP) when managing proliferative diabetic retinopathy (P

174 injections, and panretinal photocoagulation (PRP), as well as visual acuity at baseline and at 1 year

175 hotographs, (2) panretinal photocoagulation (PRP), or (3) pars plana vitrectomy (PPV) for PDR; and st

176 efore and after panretinal photocoagulation (PRP).

177 (PDR) following panretinal photocoagulation (PRP).

178 Pan retinal photocoagulation (PRP) has provided an effective treatment to decrease the

179 considered for pan-retinal photocoagulation (PRP) treatment within 1 month of diagnosis.

180 Pityriasis rubra pilaris (PRP) is a rare papulosquamous disorder with limited epid

181 Treatment of pityriasis rubra pilaris (PRP) is solely based on its resemblance to psoriasis rat

182 vulgaris (PV) and pityriasis rubra pilaris (PRP).

183 pecific effect of both platelet-rich plasma (PRP) and platelet-poor plasma (PPP) on osteoblastic diff

184 The comparison used platelet-rich plasma (PRP) and platelet-poor plasma (PPP), either with or with

185 icrobial activities of platelet-rich plasma (PRP) and related plasma preparations against periodontal

186 Platelet-rich plasma (PRP) consists of platelet-derived growth factor and tran

187 se to tissue factor in platelet-rich plasma (PRP) from patients with mild or moderate hemophilia.

188 val of leukocytes from platelet-rich plasma (PRP) in a continuous flow regime.

189 Platelet-rich plasma (PRP) is used to stimulate the repair of acute and chroni

190 Platelet-rich plasma (PRP) is widely used for many clinical indications includ

191 thrombin assays using platelet-rich plasma (PRP) showed that tissue factor-triggered thrombin genera

192 rophotometric assay on platelet-rich plasma (PRP) treated with the thromboxane A2 mimetic U46619, col

193 Whole blood (WB) and platelet-rich plasma (PRP) were perfused at high shear rates (> 3,000 s(-1)) t

194 s) were performed with platelet-rich plasma (PRP), a shorter lag time was measured in 131RR donors co

195 Platelet-rich plasma (PRP), an autologous derivative of whole blood that conta

196 ng HIT antibodies than platelet-rich plasma (PRP)-based assays.

197 d markedly enhanced in platelet-rich plasma (PRP).

198 -AP and incubated with platelet-rich plasma (PRP).

199 characterization of photorefractive polymer (PRP) in a previously inaccessible regime located between

200 e and activated capsular polyribosylribitol (PRP) polysaccharides extracted from Haemophilus influenz

201 phase-referenced high gamma and beta power (PRP), in the olfactory bulb of mice learning to discrimi

202 date the first polygenic response predictor (PRP) for BB survival benefit in heart failure with reduc

203 tment and DR progression regardless of prior PRP treatment status at baseline.

204 ogression among patients who underwent prior PRP.

205 In patients with prior PRP at baseline (n = 182), 19.3% of sham-treated patient

206 No ranibizumab-treated patients with prior PRP at baseline required additional on-study PRP through

207 By month 24 in patients with prior PRP at baseline, the probability of experiencing a new p

208 In patients without prior PRP at baseline (n = 577), 9.5% of sham-treated patients

209 ring in patients both with and without prior PRP treatment at baseline.

210 e, develop the parallel residual projection (PRP), a parallel computational framework involving the d

211 n irradiated in paddy-field water, propanil (PRP) undergoes photodegradation by direct photolysis, by

212 s thaliana is a pentapeptide-repeat protein (PRP) composed of 25 repeats capped by N- and C-terminal

213 A proline-rich protein (PRP) family, composed of tandemly repeated Pro-Hyp-Val-X

214 25 and UAB-LLQ composite scores, ranibizumab-PRP treatment group differences (95% CI) were +4.0 (-0.2

215 idual eyes were randomly assigned to receive PRP treatment, completed in 1 to 3 visits (n = 203 eyes)

216 received IVI with anti-VEGF and 46 received PRP.

217 ived IVB, and 32 eyes (17 patients) received PRP.

218 being LTFU compared with eyes that received PRP.

219 ificantly decreased in patients who received PRP after 31 days compared with those treated on the day

220 respectively, and for the infants receiving PRP, these were 24.8 weeks, 701.4 g, 36.1 weeks, and 34.

221 Assays on reconstituted PRP and PRP from fibrinogen-deficient patients revealed

222 Hairpin-RNA knock-down constructs reducing PRP expression in Medicago truncatula hairy root tumors

223 pathway as a treatment option for refractory PRP.

224 ipitous therapeutic approaches in refractory PRP.

225 om this patient and 2 others with refractory PRP.

226 PRP naive at baseline who went on to require PRP, experienced more clinical events than ranibizumab-t

227 might be used to counsel patients requiring PRP and informs the debate regarding the role of anti-va

228 In RIDE and RISE, PRP treatment was not a "1 and done" procedure, with on-

229 Following the publication of Protocol S, PRP rates decreased, while anti-VEGF rates increased.

230 ic effect of the coexistence of two salivary-PRP fractions (basic-PRPs and acidic PRPs) on the intera

231 ings were highly reproducible across several PRP topographies generated in multiple cohorts of parkin

232 These data show PRP induces key aspects of post-natal maturation in imma

233 elevated levels of reactive oxygen species, PRP may connect MAPK and oxidative stress signaling.

234 ive in the context of psoriasis and sporadic PRP.

235 cral pustular psoriasis (n=100), or sporadic PRP (n=29).

236 pattern scan versus conventional single-spot PRP also were at higher risk for worsening PDR (60% vs.

237 not a "1 and done" procedure, with on-study PRP re-treatment occurring in patients both with and wit

238 PRP at baseline required additional on-study PRP through month 24 (P < 0.001 for both ranibizumab arm

239 Ranibizumab treatment reduced on-study PRP treatment and DR progression regardless of prior PRP

240 Our results suggest PRP should be investigated further as a potential point-

241 IVB was associated with less myopia than PRP, although longer follow-up was available for PRP.

242 requires a more frequent visit schedule than PRP, these findings provide additional evidence supporti

243 ity that was noninferior to (not worse than) PRP treatment at 2 years.

244 ions of the embryonic calvaria revealed that PRP leads to suture fusion.

245 linical and histologic findings suggest that PRP enhanced bone regeneration and resulted in increased

246 The PRP was constructed from a genome-wide analysis of BBxge

247 The PRP was derived in a random subset of the Henry Ford Hea

248 resented similar amounts of NBA and ABT; the PRP-BMA group showed NC formation with collagen fibers i

249 macokinetic studies were implemented and the PRP's anti-tumour efficacy was explored against orthotop

250 +2.8 in the ranibizumab group vs +0.2 in the PRP group (difference, +2.2; 95% CI, -0.5 to +5.0; P < .

251 f the tissue was significantly better in the PRP group than in the control tissue (p<0.001).

252 ence, 19%; 95% CI, 10%-28%; P < .001) in the PRP group vs the ranibizumab group, respectively.

253 In the PRP group, eyes receiving pattern scan versus convention

254 In the PRP group, mean VA worsened significantly when comparing

255 (35% in the ranibizumab group vs 30% in the PRP group; difference, 3%; 95% CI, -7% to 12%; P = .58).

256 or solving an LIP can be integrated into the PRP framework and used to solve the sub-problems while h

257 We analyze the convergence properties of the PRP and accentuate its benefits through its application

258 eovascularization (NV) leakage area than the PRP group at month 3 and month 6 after treatment, and a

259 igned to the ranibizumab group and 25 to the PRP group (plus ranibizumab for DME).

260 of the iris in the IVI arm compared with the PRP arm at the final visit (4 vs. 0, respectively; P = 0

261 etachment in the IVI group compared with the PRP group at the final visit (10 vs. 1, respectively; P

262 ytes are separated from platelets within the PRP by progressively syphoning clarified PRP away from t

263 Exposure of pancreatic CSCs spheres to PRP resulted in a significant decrease of ALDEFLUOR and

264 Aflibercept was non-inferior and superior to PRP in both the modified intention-to-treat population (

265 esponse of ruptured human Achilles tendon to PRP.

266 of ranibizumab as an alternative therapy to PRP for PDR, at least through 2 years.

267 omposed of Chymotrypsinogen and Trypsinogen (PRP) on CSCs derived from a human pancreatic cell line,

268 % of patients in RIDE and RISE had undergone PRP treatment before enrollment (22.2%, 24.4%, and 25.4%

269 Patients who underwent PRP had diffusely thickened nerve fiber layers (P = 0.02

270 Patients who underwent PRP had more profound changes in outer retinal structure

271 diagnosed as having classic, unquestionable PRP.

272 th intravitreal conbercept injections versus PRP alone in the treatment of proliferative diabetic ret

273 Intravitreous ranibizumab (0.5 mg) versus PRP for PDR.

274 e greater sensitivity of washed platelet (vs PRP) assays for HIT.

275 ness ratios of 0.5-mg ranibizumab therapy vs PRP for PDR.

276 ependent fashion, particularly in washed (vs PRP) systems.

277 anti-VEGF agents, and 36.4% (n = 3656) were PRP treatments.

278 patients, including those patients who were PRP naive at baseline who went on to require PRP, experi

279 When PRP was the primary treatment, the 2-year cost in the fa

280 parative study in order to determine whether PRP can also induce this specific form of remodeling tha

281 ial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) rando

282 CVA during the drug's lifespan compared with PRP alone.

283 tiveness ratios of ranibizumab compared with PRP evaluated within 2 prespecified subgroups for the st

284 ratios of ranibizumab therapy compared with PRP were $55568/quality-adjusted life-year and $662978/q

285 Over 2 years, compared with PRP, 0.5-mg ranibizumab as given in this trial is within

286 resulted in less PDR worsening compared with PRP, especially in eyes not required to receive ranibizu

287 , the rate of PDR-worsening was greater with PRP than ranibizumab (45% vs. 31%; HR, 1.62; 99% CI, 1.0

288 parations can inhibit bacterial growth, with PRP showing the superior activity.

289 Radiographs of alginate hydrogel with PRP-treated bone demonstrated nearly complete healing of

290 In this case report, a patient with PRP received outpatient treatment at a university hospit

291 The patient with PRP who received ustekinumab showed regression of skin l

292 etime therapy yielded the cost per QALY with PRP treatment of $14 219 to $24 005 and with IVR of $138

293 were assessed every 8 weeks and treated with PRP as needed) for 52 weeks.

294 Wounds treated with PRP coacervate exhibited increased collagen alignment an

295 ompared with controls, patients treated with PRP demonstrated increased photostress recovery time (15

296 patients diagnosed with PDR and treated with PRP from 2015 to the present.

297 e at 1 year compared with those treated with PRP standard care.

298 umber of zone I and II ROP eyes treated with PRP were 5 and 27, respectively.

299 performed on human cancer cells treated with PRP.

300 nse of ruptured Achilles tendon treated with PRP.

301 Achilles tendon 6 weeks after treatment with PRP or placebo controls (10 patients each).

302 randomly assigned to receive treatment with PRP, and the other eye received conbercept combined PRP.